Literature DB >> 27994688

Iodine Uptake Patterns on Post-ablation Whole Body Scans are Related to Elevated Serum Thyroglobulin Levels After Radioactive Iodine Therapy in Patients with Papillary Thyroid Carcinoma.

Geum-Cheol Jeong1, Minchul Song1, Hee Jeong Park1, Jung-Joon Min1, Hee-Seung Bom1, Sang-Geon Cho1, Ki Seong Park2, Sae-Ryung Kang2, Jahae Kim2, Ho-Chun Song2, Seong Young Kwon1.   

Abstract

PURPOSE: Serum thyroglobulin (Tg) level is frequently elevated shortly after radioactive iodine (RAI) ablation therapy. The authors studied the relationship between the elevation of serum Tg after RAI therapy and iodine uptake pattern on post-ablation whole body scans (RxWBSs) in patients with papillary thyroid carcinoma (PTC).
MATERIALS AND METHODS: The study subjects were patients with PTC that had undergone first RAI therapy with thyroid hormone withdrawal after total thyroidectomy. Patients with a high level of serum anti-Tg antibody (TgAb, ≥ 60 U/mL), possible regional or distant metastasis as determined by pre-ablation or post-ablation studies, and negative iodine uptake of the anterior neck on RxWBS were excluded. Serum Tg was checked twice, that is, 7 days after (post-ablation Tg) and on the day of RAI therapy (pre-ablation Tg). Ratio of pre-ablation Tg to post-ablation Tg (Tg ratio) was used to assess changes in serum Tg levels after RAI therapy. Patients were classified into two groups according to the presence of midline uptake above the thyroidectomy bed on RxWBS (negative (group 1) or positive (group 2) midline uptake). Variables were subjected to analysis to identify differences between the two groups.
RESULTS: Two hundred and fifty patients were enrolled in this study; 101 in group 1 and 149 in group 2. Based on univariate analysis, post-ablation Tg (8.12 ± 11.05 vs. 34.12 ± 54.31; P < 0.001) and Tg ratio (7.81 ± 8.98 vs. 20.01 ± 19.84; P < 0.001) were significantly higher in group 2. On the other hand, gender, tumor (T) stage, lymph node (N) stage, size, multiplicity or bilaterality of primary tumor, dose of 131I, serum TgAb and thyroid-stimulating hormone (TSH) level (before or after RAI therapy) were not significantly different in the two groups. Variables with P values of < 0.25 by univariate analysis were subjected to multivariate analysis, which showed post-ablation Tg (OR 1.060, 95 % CI = 1.028-1.092; P < 0.001) and Tg ratio (OR 1.059, 95 % CI = 1.028-1.092; P = 0.001) were significantly higher in group 2.
CONCLUSION: Serum Tg level after RAI therapy was significantly higher in patients with midline uptake on RxWBS, compared with patients without midline uptake on RxWBS. Further investigations are needed to reveal the correlation between serum Tg elevation and clinical outcome according to the presence of midline uptake.

Entities:  

Keywords:  Papillary thyroid carcinoma; Radioactive iodine therapy; Thyroglobulin; Thyroglossal duct remnants; Whole body scan

Year:  2016        PMID: 27994688      PMCID: PMC5135694          DOI: 10.1007/s13139-016-0421-1

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  28 in total

1.  Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.

Authors:  Anna M Sawka; Steven Orlov; Jacob Gelberg; Barry Stork; Mark Dowar; Michael Shaytzag; Vafa Tabatabaie; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

2.  Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma.

Authors:  Hyo Jin Lee; So Young Rha; Young Suk Jo; Seong Min Kim; Bon Jeong Ku; Minho Shong; Young Kun Kim; Heung Kyu Ro
Journal:  Am J Clin Oncol       Date:  2007-02       Impact factor: 2.339

3.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

4.  Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.

Authors:  Marie-Odile Bernier; Olivier Morel; Patrice Rodien; Jean-Pierre Muratet; Philippe Giraud; Vincent Rohmer; Christian Jeanguillaume; Jean-Claude Bigorgne; Pierre Jallet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

5.  Ultrasound characteristics of thyroglossal duct anomalies.

Authors:  R J Baatenburg de Jong; R J Rongen; J S Laméris; P Knegt; C D Verwoerd
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1993 Sep-Oct       Impact factor: 1.538

6.  Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer.

Authors:  Daniel B Kendler; Fernanda Vaisman; Rossana Corbo; Rosângela Martins; Mario Vaisman
Journal:  Clin Nucl Med       Date:  2012-06       Impact factor: 7.794

7.  Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.

Authors:  Alon Vaisman; Steven Orlov; Jonathan Yip; Cindy Hu; Terence Lim; Mark Dowar; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2010-06       Impact factor: 3.147

8.  Clinical significance of diffuse hepatic visualization and thyroid bed uptake on post-ablative iodine-131 whole body scan in differentiated thyroid cancer.

Authors:  Keunyoung Kim; Seong-Jang Kim; In-Joo Kim; Yong-Ki Kim; Bum Soo Kim; Kyoungjune Pak
Journal:  Onkologie       Date:  2012-02-24

9.  Enhanced scintigraphic visualization of thyroglossal duct remnant during hypothyroidism after total thyroidectomy: prevalence and clinical implication in patients with differentiated thyroid cancer.

Authors:  Sang-Woo Lee; Jaetae Lee; Hui Joong Lee; Ji-Hyoung Seo; Seong-Min Kang; Jin-Ho Bae; Byeong-Cheol Ahn
Journal:  Thyroid       Date:  2007-04       Impact factor: 6.568

Review 10.  Papillary carcinoma arising in a thyroglossal duct cyst: a case report and literature review.

Authors:  A W Hilger; S D Thompson; L A Smallman; J C Watkinson
Journal:  J Laryngol Otol       Date:  1995-11       Impact factor: 1.469

View more
  5 in total

1.  Expression of autophagy-associated proteins in papillary thyroid carcinoma.

Authors:  Meiliu Yang; Lu Bai; Wu Yu; Xueling Sun; Gang Xu; Ruhua Guan; Ying Yang; Mingyue Qiu; Yazhong Zhang; Jinli Tian; Hui Fang
Journal:  Oncol Lett       Date:  2017-04-28       Impact factor: 2.967

2.  The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.

Authors:  Hee Kyung Kim; Jee Hee Yoon; Jin Seong Cho; Seong Young Kwon; Su Woong Yoo; Ho-Cheol Kang
Journal:  Korean J Intern Med       Date:  2019-07-29       Impact factor: 2.884

3.  Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by Recombinant Human Thyrotropin in Patients with Differentiated Thyroid Cancer.

Authors:  Minchul Song; Subin Jeon; Sae-Ryung Kang; Zeenat Jabin; Su Woong Yoo; Jung-Joon Min; Hee-Seung Bom; Sang-Geon Cho; Jahae Kim; Ho-Chun Song; Seong Young Kwon
Journal:  Nucl Med Mol Imaging       Date:  2018-06-04

4.  Optimization of Predictive Performance for the Therapeutic Response Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma.

Authors:  Su Woong Yoo; Md Sunny Anam Chowdhury; Subin Jeon; Sae-Ryung Kang; Sang-Geon Cho; Jahae Kim; Changho Lee; Young Jae Ryu; Ho-Chun Song; Hee-Seung Bom; Jung-Joon Min; Seong Young Kwon
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

5.  A Stepwise Approach Using Metastatic Lymph Node Ratio-Combined Thyroglobulin for Customization of [18F]FDG-PET/CT Indication to Detect Persistent Disease in Patients with Papillary Thyroid Cancer.

Authors:  Hong Hua Piao; Subin Jeon; Su Woong Yoo; Young Jae Ryu; Dong-Yeon Kim; Ayoung Pyo; Hee-Seung Bom; Jung-Joon Min; Seong Young Kwon
Journal:  Diagnostics (Basel)       Date:  2021-05-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.